Addition of treosulfan to a nonmyeloablative conditioning regimen results in enhanced chimerism and immunologic tolerance in an experimental allogeneic bone marrow transplant model

Biology of Blood and Marrow Transplantation

Volumn 10, Issue 4, 2004, Pages 236-245

  Ploemacher, Rob E ^a   Johnson, Kevin W ^b   Rombouts, Elwin J C ^a   Etienne, Kenol ^b   Westerhof, G Robbin ^a   Baumgart, Joachim ^c   White Scharf, Mary E ^b   Down, Julian D ^b,d  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^b BioTransplant Inc   (United States)

^c MEDAC GMBH   (Germany)

^d HARVARD INSTITUTES OF MEDICINE   (United States)

Author keywords

Allogeneic bone marrow engraftment; Donor lymphocyte infusion; Immune tolerance; Nonmyeloablative conditioning; Treosulfan

Indexed keywords

BUSULFAN; CD4 ANTIGEN; CD8 ANTIGEN; FLUDARABINE; FLUDARABINE PHOSPHATE; MONOCLONAL ANTIBODY; TREOSULFAN;

ADOPTIVE IMMUNOTHERAPY; ALLOGENIC BONE MARROW TRANSPLANTATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW SUPPRESSION; CELL ASSAY; CHIMERA; CLINICAL PROTOCOL; CONTROLLED STUDY; DEPLETION; DOSE RESPONSE; DRUG MECHANISM; EXPERIMENTAL MODEL; FEMALE; FREQUENCY ANALYSIS; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; IRRADIATION; LOW DRUG DOSE; LYMPHOCYTE DEPLETION; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MOUSE; NONHUMAN; OVARY CANCER; SKIN GRAFT; T LYMPHOCYTE; THYMUS;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; BONE MARROW; BONE MARROW TRANSPLANTATION; BUSULFAN; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELLS; MALE; MICE; T-LYMPHOCYTES; TRANSPLANTATION CHIMERA; TRANSPLANTATION CONDITIONING;

EID: 1842531123     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbmt.2003.11.004     Document Type: Article

References (50)

1. Loeb V. Jr. Dihydroxybusulfan (NSC-39069) in chronic myelocytic leukemia and miscellaneous malignant neoplasms Cancer Chemother Rep. 42 1964 39-43
2. Gropp M. Meier W. Hepp H. Treosulfan as an effective second-line therapy in ovarian cancer Gynecol Oncol. 71 1998 94-98
3. Masding J. Sarkar T.K. White W.F. et al. Intravenous treosulfan versus intravenous treosulfan plus cisplatinum in advanced ovarian carcinoma Br J Obstet Gynaecol. 97 1990 342-351
4. Merkle E. Ackermann S. Beck E.P. et al. High-dose versus low-dose cisplatin chemotherapy plus treosulfan in epithelial ovarian carcinoma FIGO II-IV: results of a prospective randomized trial Onkologie 23 2000 232-238
5. Köpf-Maier P. Saß G. Antitumor activity of treosulfan in human lung carcinomas Cancer Chemother Pharmacol. 37 1996 211-221
6. Köpf-Maier P. The alkylator treosulfan shows activity towards human renal-cell carcinoma in vivo and in vitro In Vivo 12 1998 275-288
7. Neale M.H. Myatt N. Cree I.A. et al. Combination chemotherapy for choroidal melanoma: ex vivo sensitivity to treosulfan with gemcitabine or cytosine arabinoside Br J Cancer 79 1999 1487-1493
8. Neuber K. tom Dieck A. Blödorn-Schlicht N. et al. Treosulfan is an effective alkylating cytostatic for malignant melanoma in vitro and in vivo Melanoma Res. 9 1999 125-132
9. Topaly J. Fruehauf S. Ho A.D. et al. Rationale for combination therapy of chronic myelogenous leukaemia with imatinib and irradiation or alkylating agents: implications for pretransplant conditioning Br J Cancer 86 2002 1487-1493
10. Schmidmaier R. Oellerich M. Baumgart J. et al. Treosulfan induced apoptosis in AML cells is accompanied by translocation of PKC delta and enhanced by bryostatin-1 Exp Hematol. 32 2004 76-86
11. Fichtner I. Becker M. Baumgart J. Antileukemic activity of treosulfan in xenografted human acute lymphoblastic leukemias (ALL) Eur J Cancer 39 2003 801-807
12. Meinhardt G. Dayyani F. Jahrsdörfer B. et al. Treosulfan is an effective inducer of cell death in myeloma cell lines and primary myeloma cells from patients Br J Haematol. 122 2003 1-8
13. Hartley J.A. O'Hare C.C. Baumgart J. DNA alkylation and interstrand cross-linking by treosulfan Br J Cancer 79 1999 264-266
14. Harstrick A. Wilke H. Eberhardt W. et al. A phase I dose escalation trial of intravenous treosulfan in refractory cancer Onkologie 19 1996 153-156
15. Scheulen M.E. Hilger R.A. Oberhoff C. et al. Clinical phase I dose escalation and pharmacokinetic study of high-dose chemotherapy with treosulfan and autologous peripheral blood stem cell transplantation in patients with advanced malignancies Clin Cancer Res. 6 2000 4209-4216
16. Casper J. Knauf W. Kiefer T. Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation Blood 103 2004 725-731
17. Westerhof G.R. Ploemacher R.E. Boudewijn A. et al. Comparison of different busulfan analogues for depletion of hematopoietic stem cells and promotion of donor-type chimerism in murine bone marrow transplant recipients Cancer Res 60 2000 5470-5478
18. Down J.D. Ploemacher R.E. Transient and permanent engraftment potential of murine hematopoietic stem cell subsets: different effects of host conditioning with gamma radiation and cytotoxic drugs Exp Hematol. 21 1993 913-921
19. Spitzer T.R. Nonmyeloablative allogeneic stem cell transplant strategies and the role of mixed chimerism Oncologist 5 2000 215-223
20. Molina A.J. Sandmaier B.M. Storb R. Nonmyeloablative hematopoietic stem cell allografting Curr Opin Organ Transplant. 5 2000 366-371
21. Alyea E.P. Neuberg D. Canning C. et al. Nonmyeloablative conditioning with low dose intravenous busulfan and fludarabine is safe and sufficient to obtain allogeneic stem cell engraftment in patients with hematologic malignancies Blood 98 2001 S185a (abstr.)
22. Bornhauser M. Thiede C. Schuler U. et al. Dose-reduced conditioning for allogeneic blood stem cell transplantation: durable engraftment without antithymocyte globulin Bone Marrow Transplant. 26 2000 119-125
23. Slavin S. Nagler A. Naparstek E. et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases Blood 91 1998 756-763
24. Khouri I.F. Keating M. Korbling M. et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies J Clin Oncol. 16 1998 2817-2824
25. Childs R. Clave E. Contentin N. et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses Blood 94 1999 3234-3241
26. Childs R. Chernoff A. Contentin N. et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation N Engl J Med. 343 2000 750-758
27. Spitzer T.R. McAfee S. Sackstein R. et al. Intentional induction of mixed chimerism and achievement of antitumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies Biol Blood Marrow Transplant 6 2000 309-320
28. Juliusson G. Karlsson K. Frodin U. Backstrom G. Malm C. Subcutaneous Campath1H instead of thymoglobulin in nonmyeloablative allogeneic transplantation: reduced acute toxicity, but delayed lymphocyte recovery leading to more Mixed chimerism, more fatal infections and impaired long-term survival-a single center study of 56 patients Blood 100 2002 S430a (abstr.)
29. Robertson M.J. Bierman P. Bolwell B.J. et al. Safety and biological activity of siplizumab (AlloMune®component II: MEDI-507) in non-myeloablative allogeneic peripheral blood stem cell transplantation (NMAT) for refractory non-Hodgkin's lymphoma (NHL) Blood 100 2002 S426a (abstr.)
30. Spitzer T.R. McAfee S.L. Dey B.R. et al. Nonmyeloablative haploidentical stem-cell transplantation using anti-CD2 monoclonal antibody (MEDI-507)-based conditioning for refractory hematologic malignancies Transplantation 75 2003 1748-1751
31. Holler E. Trenschel R. Casper J. et al. Treosulfan/cyclophosphamide conditioning in high-risk leukemia patients. A clinical phase I and pharmacokinetic study Bone Marrow Transplant. 31 2003 174 (abstr.)
32. Beelen D.W. Trenschel R. Casper J. et al. Evaluation of safety, efficacy and pharmacokinetics of dose-escalated treosulfan (TREO)/cyclophosphamide (CY) conditioning prior to allogeneic transplantation of high-risk leukemia patients Blood 100 2002 415a (abstr.)
33. Ploemacher R.E. van der Sluijs J.P. van Beurden C.A.J. et al. Use of limiting-dilution type long-term marrow cultures in frequency analysis of marrow-repopulating and spleen colony-forming hematopoietic stem cells in the mouse Blood 78 1991 2527-2533
34. Ploemacher R.E. van der Sluijs J.P. Voerman J.S.A. et al. An in vitro limiting-dilution assay of long-term repopulating hematopoietic stem cells in the mouse Blood 74 1989 2755-2763
35. Ploemacher R.E. Van der Loo J.C.M. Van Beurden C.A.J. Baert M.R.M. Wheat germ agglutinin affinity of hemopoietic stem cell subpopulations is an inverse function of their long term repopulating ability in vitro and in vivo Leukemia 7 1993 120-130
36. Ploemacher R.E. Westerhof G.R. Blokland I. Baumgart J. Down J.D. Treosulfan as an alternative conditioning agent in bone marrow transplantation Bone Marrow Transplant. 25 suppl 1 2000 421 (abstr.)
37. Sharabi Y. Sachs D.H. Mixed chimerism and permanent specific transplantation tolerance induced by a nonlethal preparative regimen J Exp Med. 169 1989 493-502
38. Adams A.B. Durham M.M. Kean L. et al. Costimulation blockade, busulfan, and bone marrow promote titratable macrochimerism, induce transplantation tolerance, and correct genetic hemoglobinopathies with minimal myelosuppression J Immunol. 167 2001 1103-1111
39. Andersson G. Illigens B.M.W. Johnson K.W. et al. Nonmyeloablative conditioning is sufficient to allow engraftment of EGFP-expressing bone marrow and subsequent acceptance of EGFP-transgenic skin grafts in mice Blood 101 2003 4305-4312
40. Down J.D. Boudewijn A. van Os R. Thames H.D. Ploemacher R.E. Variations in radiation sensitivity and repair among different hematopoietic stem cell subsets following fractionated irradiation Blood 86 1995 122-127
41. van Pel M. van Breugel D.W.J.G. Vos W. et al. Towards a myeloablative regimen with clinical potential: I. Treosulfan conditioning and bone marrow transplantation allow induction of donor-specific tolerance for skin grafts across full MHC barriers Bone Marrow Transplant. 32 2003 15-22
42. Pelot M.R. Pearson D.A. Swenson K. et al. Lymphohematopoietic graft-vs.-host reactions can be induced without graft-vs.-host disease in murine mixed chimeras established with a cyclophosphamide-based nonmyeloablative conditioning regimen Biol Blood Marrow Transplant. 5 1999 133-143
43. Sykes M. Szot G.L. Swenson K. Pearson D.A. Wekerle T. Separate regulation of peripheral hematopoietic and thymic engraftment Exp Hematol. 26 1998 457-465
44. Giralt S. Thall P.F. Khouri I. et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation Blood 97 2001 631-637
45. Slavin S. Immunotherapy of cancer with alloreactive lymphocytes N Engl J Med. 343 2000 802-803
46. Down J.D. White-Scharf M.E. Re-programming immune responses: enabling cellular therapies and regenerative medicine Stem Cells 21 2003 21-32 [review]
47. Keil F. Haas O. Fritsch G. et al. Donor leukocyte infusion for leukemic relapse after allogeneic marrow transplantation: lack of residual donor hematopoiesis predicts aplasia Blood 89 1997 3113-3117
48. Baurmann H. Nagel S. Binder T. et al. Kinetics of the graft versus-leukemia response after donor leukocyte infusions for relapsed chronic myeloid leukemia after allogeneic bone marrow transplantation Blood 92 1998 3582-3590
49. Gardiner N. Lawler M. O'Riordan J. et al. Monitoring of lineage specific chimerism allows early prediction of response following donor lymphocyte infusions for relapsed chronic myeloid leukaemia Bone Marrow Transplant. 21 1998 711-719
50. Orsini E. Alyea E.P. Chillemi A. et al. Conversion to full donor chimerism following donor lymphocyte infusion is associated with disease response in patients with multiple myeloma Biol Blood Marrow Transplant. 6 2000 375-386